首页> 外文期刊>British Journal of Cancer >Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy
【24h】

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

机译:诱导化疗后非小细胞肺癌的加速再生

获取原文
           

摘要

Induction chemotherapy of non-small-cell lung cancer (NSCLC) stage III with gemcitabine and cisplatin for downstaging of the tumour with the aim for further treatment with ionising radiation is one of the treatments for lung cancer patients. The purpose of this study was to investigate the influence of the waiting time for radiotherapy, that is, the interval between induction chemotherapy and radiotherapy, on the rate of tumour growth for patients with NSCLC. Interval times between the end of induction chemotherapy and date of diagnostic CT, planning CT and first day of radiotherapy were determined for 23 patients with NSCLC. Increase in gross tumour volume was measured for 18 patients by measuring the dimensions of the primary tumour and lymph node metastases on the diagnostic CT after induction chemotherapy and on the CT used for radiotherapy planning. For each patient, the volume doubling time was calculated from the time interval between the two CTs and ratio of the gross volumes on planning CT and diagnostic CT. The mean time interval between end of chemotherapy and day of diagnostic CT was 16 days, and till first day of radiotherapy 80.3 (range 29 – 141) days. In all, 41% of potentially curable patients became incurable in the waiting period. The ratio of gross tumour volumes of the two CTs ranged from 1.1 to 81.8 and the tumour doubling times ranged from 8.3 to 171 days, with a mean value of 46 days and median value of 29 days. This is far less than the mean doubling time of NSCLC in untreated patients found in the literature. This study shows that in the time interval between the end of induction chemotherapy and the start of radiotherapy rapid tumour progression occurs as a result of accelerated tumour cell proliferation: mean tumour doubling times are much shorter than those in not treated tumours. As a consequence, the gain obtained with induction chemotherapy with regard to volume reduction was lost in the waiting time for radiotherapy. We recommend diminishing the time interval between chemo- and radiotherapy to as short as possible.
机译:吉西他滨和顺铂对非小细胞肺癌(NSCLC)III期进行诱导化疗以降低肿瘤分期,目的是进一步用电离辐射治疗是肺癌患者的治疗方法之一。这项研究的目的是调查放疗的等待时间,即诱导化疗和放疗之间的间隔,对非小细胞肺癌患者肿瘤生长速率的影响。确定了23例NSCLC患者的诱导化疗结束与诊断CT日期,计划CT和放疗第一天之间的间隔时间。通过测量诱导化疗后诊断性CT和用于放射治疗计划的CT上原发性肿瘤和淋巴结转移的大小,对18例患者的总肿瘤体积增加进行了测量。对于每位患者,从两次CT之间的时间间隔以及计划CT和诊断CT上总体积的比率来计算体积加倍时间。从化疗结束到诊断CT的一天之间的平均时间间隔为16天,到放疗的第一天80.3天(范围29 – 141)。在等待期间,总共有41%的可能治愈的患者变得无法治愈。两次CT的总肿瘤体积比为1.1至81.8,肿瘤倍增时间为8.3至171天,平均值为46天,中位数为29天。这远远小于文献中未治疗患者的NSCLC平均加倍时间。这项研究表明,在诱导化疗结束与放疗开始之间的时间间隔内,由于肿瘤细胞增殖加速,导致肿瘤快速进展:平均肿瘤倍增时间比未治疗的肿瘤要短得多。结果,在放疗的等待时间中损失了诱导化学疗法在减少体积方面的收益。我们建议将化学疗法和放射疗法之间的时间间隔尽可能缩短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号